DOCSLIB.ORG

Pandemic.Pdf.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pandemic.Pdf.Pdf 1 PANDEMICS: Past, Present, Future Published in 2021 by the Mahatma Gandhi Institute of Education for Peace and Challenges & Opportunities Sustainable Development, 35 Ferozshah Road, New Delhi 110001, India © UNESCO MGIEP This publication is available in Open Access under the Attribution-ShareAlike Coordinating Lead Authors: 3.0 IGO (CC-BY-SA 3.0 IGO) license (http://creativecommons.org/licenses/ ANANTHA KUMAR DURAIAPPAH by-sa/3.0/ igo/). By using the content of this publication, the users accept to be Director, UNESCO MGIEP bound by the terms of use of the UNESCO Open Access Repository (http:// www.unesco.org/openaccess/terms-use-ccbysa-en). KRITI SINGH Research Officer, UNESCO MGIEP The designations employed and the presentation of material throughout this publication do not imply the expression of any opinion whatsoever on the part of UNESCO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The ideas and opinions expressed in this publication are those of the authors; they Lead Authors: NANDINI CHATTERJEE SINGH are not necessarily those of UNESCO and do not commit the Organization. Senior Programme Officer, UNESCO MGIEP The publication can be cited as: Duraiappah, A. K., Singh, K., Mochizuki, Y. YOKO MOCHIZUKI (Eds.) (2021). Pandemics: Past, Present and Future Challenges and Opportunities. Head of Policy, UNESCO MGIEP New Delhi. UNESCO MGIEP. SHAHID JAMEEL Coordinating Lead Authors: Director, Trivedi School of Biosciences, Ashoka University Anantha Kumar Duraiappah, Director, UNESCO MGIEP Kriti Singh, Research Officer, UNESCO MGIEP Lead Authors: Nandini Chatterjee Singh, Senior Programme Officer, UNESCO MGIEP Contributing Authors: CHARLES PERRINGS Yoko Mochizuki, Head of Policy, UNESCO MGIEP Global Institute of Sustainability, Arizona State University Shahid Jameel, Director, Trivedi School of Biosciences, Ashoka University W. IAN LIPKIN Contributing Authors: John Snow Professor of Epidemiology, Charles Perrings, Professor of Environmental Economics, Vice-Chair, Diversitas, Mailman School of Public Health, Columbia University; Global Institute of Sustainability, Arizona State University W. Ian Lipkin, John Snow Professor of Epidemiology, Mailman School of Public Professor of Neurology and Pathology, Health, Columbia University; Professor of Neurology and Pathology, College of College of Physicians and Surgeons, Columbia University Physicians and Surgeons, Columbia University B.N. Satpathy, Senior Consultant, Office of Principal Scientific Advisor to the B.N. SATPATHY Government of India Senior Consultant, Suneet Mohan, Consultant, Office of Principal Scientific Advisor to the Office of Principal Scientific Advisor to the Government of India Government of India Devesh Kumar, Consultant, UNESCO MGIEP SUNEET MOHAN Designed by Prasun Mazumdar Design, Gurgaon, India Consultant, Printed by Lustra Printing Press Office of Principal Scientific Advisor to the Government of India Printed in India DEVESH KUMAR Consultant, UNESCO MGIEP 3 Preface Please note: The research, and findings presented in this The booklet took about 6 months till its completion. document are based on data collected until January, 2021. It was a herculean task as the goal posts kept changing, we were flooded with new information on a daily basis As the world continues to grapple with COVID-19, regarding a relatively new phenomena. However, as this booklet comes in handy to answer and reflect upon we sailed through uncharted waters and endured the basic questions encompassing the word “pandemic”- the hurdles, we believe we have a story to tell through this what, where, when and how of it. The genesis of the booklet and hope the readers find it useful primarily as book began when we were approached by the Office of an information note on pandemics in general. It also Principal Scientific Adviser to the Government of highlights some of the complexities we have to face India to produce a document that was not meant to be: when making decisions to combat the disease but at (i) a compendium for training individuals on pandemic the same time oversee the welfare of the people across science; (ii) an exhaustive compilation of do’s and don’ts multiple domains and not just linked with the disease. with respect to a pandemic; and iii) a commentary on global best versus worst practices to combat the We acknowledge that an exhaustive evaluation of the pandemic. current pandemic- COVID-19 and its aftermath might not be possible, given that it is still ongoing and we What this booklet does aim to provide is the following: make no such claims. However, we do try to gauge the (i) basic information about key concepts associated with magnitude of its impact on the world we live in and and procedural understanding of the term “pandemic”; derive preliminary inferences based on facts to enhance (ii) a synopsis of past and present pandemics with our understanding. focus on lessons learnt- primarily from COVID-19 and preparedness for future; iii) a brief overview of If there is one thing that the COVID-19 pandemic has mitigation policies adopted by countries across the globe revealed it is the power of oneness- power of global to combat the pandemic iv) an account of direct and coordination, international scientific collaboration, and indirect impacts of pandemic on various sectors of the aligned action in fighting against the virus. We are all society ranging from health, education, to economic, in this together. As we learn to live with the fact that and v) a preliminary inference of its ramifications COVID-19 is here to stay for a while, and continue to on progress towards Sustainable Development Goals acclimatize to the “new normal”, our aim should be (SDGs). Therefore, this booklet should be considered to trust scientific evidence and align our actions in a as a primer on pandemics with the main objective of manner that maximizes “normal” living and minimizes familiarizing its readers with key concepts, measures, inconveniences caused due to the pandemic. We hope lessons and preparedness on pandemics. this booklet will provide its audience with necessary information to help achieve this goal. 5 04 TABLE OF CONTENTS Foreword 9 Q5 38 Q10 66 Q15 102 Executive Summary 10 What are the causes What are the health impacts What have been the Introduction 16 of emerging infectious of COVID-19? economic policies in response diseases? to COVID-19? Q1 18 Q6 42 Q11 74 Q16 106 What is a pandemic and how Which are the main pandemic What health sector specific What have been the overall is a pandemic declared? viruses and what are the key policy responses can be effects of COVID-19 on the differences across them and implemented? SDGs? the type of treatments used? Q2 22 Q7 48 Q12 78 Q17 112 What is the procedure used What are the main causes How has COVID-19 impacted What are the key lessons we to declare a pandemic? or drivers behind the school education? can learn from the COVID-19 emergence of pandemic pandemic and opportunities diseases? to be explored in preparation for future pandemics? Q3 26 Q8 52 Q13 86 Is it legally binding for all What are the factors What are some key policy References 120 countries to adhere to affecting the spread responses in education? pandemic guidelines? Can of pandemics? a country defy a pandemic declaration? Q4 30 Q9 56 Q14 92 What pandemics have we What measures were What have been the witnessed over the past 100 adopted by countries to economic impacts of years? combat COVID-19 and how COVID-19? successful have they been? Foreword COVID-19 pandemic is unprecedented in human This document is a collation of facts and figures history. It has brought to the forefront some which are informational in nature. It highlights some unimaginable challenges and has highlighted the need of the complexities we have to face as a nation when for resilient and adaptable health, economic, and social making decisions to combat the disease but the same systems. It is only through an unwavering commitment time oversee the welfare of the people across multiple to COVID appropriate behaviour and adoption of an domains and not just linked with the disease. I hope integrated approach towards vaccine development that that this document will serve as a useful tool not only we can mitigate and recover from damage caused by for policymakers who are at the forefront of devising pandemics like COVID-19. plans to combat the spread of disease, but also for other stakeholders like educators, economists, health care As the world continues to grapple with this pandemic, personnel who are tasked with implementing the plans, it is essential to understand the basic questions and most importantly people by and large who are encompassing the word “pandemic”- the what, where, ultimately responsible for executing the plans, thereby when and how of it. This is the motivation for the deciding success or failure in curtailing the spread of the document. disease. The primary aim of this document is to provide basic I would like to congratulate Prof Anantha Kumar information about key concepts associated with and Duraiappah, Director UNESCO MGIEP, his entire procedural understanding of the term “pandemic”. It team and the eminent contributors in taking the itiative gives a synopsis of past and present pandemics with and bringing out this document focus on lessons learnt primarily from COVID-19 and preparedness for future. It sheds light on the mitigation Lastly, I thank my team consisting of Shri B.N. policies adopted by countries across the globe to combat Satpathy and Shri Suneet Mohan for coordinating and the pandemic and gives an account of direct and indirect contributing towards building of this document impacts of pandemic on various sectors of the society. K. VIJAYRAGHAVAN Principle Scientific Advisor to the Govt. of India 9 It is against this background that well as reports from the relevant this document has been prepared.
Load more

Recommended publications
  • An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages
    International Immunopharmacology 96 (2021) 107763 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages Hamid Motamedi a, Marzie Mahdizade Ari b, Shirin Dashtbin b, Matin Fathollahi a, Hadi Hossainpour a, Amirhoushang Alvandi a,c, Jale Moradi a, Ramin Abiri a,d,* a Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran c Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran d Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran ARTICLE INFO ABSTRACT Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading COVID-19 pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic SARS-CoV-2 variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An Vaccines acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (repli­ cating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages.
    [Show full text]
  • Flattening the Curve: 3/9/2020 We’Re All in This Together, Together We Can Stop the Spread and We All Have a Role to Play
    3/23/2020 HOW TO DO IT Flattening the Curve: 3/9/2020 We’re all in this together, Together We Can Stop the Spread and we all have a role to play. • Practice social distancing. This means staying at of COVID-19 & Save Lives least six feet away from others. Without social distancing, people who are sick with COVID-19 will likely infect between 2-3 other people, and The COVID-19 pandemic is continuing to expand and affect our the spread of the virus will continue to grow. community. By making some important changes to the way we live • Stay home and away from public places, and interact with one another, we can stop the spread and save lives. especially if you are sick. • Wash your hands frequently with soap and water. • Cover your nose and mouth with a tissue when FLATTENING THE CURVE coughing and sneezing, throw the tissue away and then wash your hands. If the COVID-19 pandemic If we can slow the spread, That’s why public health orders that promote social • Avoid touching your face including your eyes, continues to grow at the just as many people might nose and mouth. current pace, it will eventually get sick, but the distancing are being put in overwhelm our health care added time will allow our place. By flattening the curve • Disinfect frequently touched objects and system, and in-turn, increase health care system to — reducing the number of surfaces, like door knobs and your phone. the number of people who provide lifesaving care to the people who will get experience severe illness or people who need it.
    [Show full text]
  • COVIPENDIUM Aug4.Pdf
    COVIPENDIUM Information available to support the development of medical countermeasures and interventions against COVID-19 Cite as: Martine DENIS, Valerie VANDEWEERD, Rein VERBEEKE, Anne LAUDISOIT, Tristan REID, Emma HOBBS, Laure WYNANTS & Diane VAN DER VLIET. (2020). COVIPENDIUM: information available to support the development of medical countermeasures and interventions against COVID-19 (Version 2020-08-04). Transdisciplinary Insights. This document is conceived as a living document, updated on a weekly basis. You can find its latest version at: https://rega.kuleuven.be/if/corona_covid-19. The COVIPENDIUM is based on open-access publications (scientific journals and preprint databases, communications by WHO and OIE, health authorities and companies) in English language. Please note that the present version has not been submitted to any peer-review process. Any comment / addition that can help improve the contents of this review will be most welcome. For navigation through the various sections, please click on the headings of the table of contents and follow the links marked in blue in the document. Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane Van der Vliet COVIPENDIUM version: 04 AUG 2020 Transdisciplinary Insights - Living Paper | 1 Contents List of abbreviations .......................................................................................................................................................... 9 Introduction ...................................................................................................................................................................
    [Show full text]
  • WHO COVID-19 Database Search Strategy (Updated 26 May 2021)
    Search purpose: Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Use following commands to pull daily new entries: Entry_date:( [20210101 TO 20210120]) Entry_date:( 20210105) Duplicates: Duplicates are found in EndNote and Distillr using the Wichor method. Further screening is done by expert reviewers but some duplicates may still be in the database. Daily Search Strategy: Database Daily Search Strategy Medline (coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR (Ovid) nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus* OR 1946- NCOV19 OR solidarity trial OR operation warp speed OR COVAX OR "ACT-Accelerator" OR BNT162b2 OR comirnaty OR "mRNA-1273" OR CoviShield OR AZD1222 OR Sputnik V OR CoronaVac OR "BBIBP-CorV" OR "Ad26.CoV2.S" OR "JNJ-78436735" OR Ad26COVS1 OR VAC31518 OR EpiVacCorona OR Convidicea OR "Ad5-nCoV" OR Covaxin OR CoviVac OR ZF2001 OR "NVX-CoV2373" OR "ZyCoV-D" OR CIGB 66 OR CVnCoV OR "INO-4800" OR "VIR-7831" OR "UB-612" OR BNT162 OR Soberana 1 OR Soberana 2 OR "B.1.1.7" OR "VOC 202012/01" OR "VOC202012/01" OR "VUI 202012/01" OR "VUI202012/01" OR "501Y.V1" OR UK Variant OR Kent Variant OR "VOC 202102/02" OR "VOC202102/02" OR "B.1.351" OR "VOC 202012/02" OR "VOC202012/02" OR "20H/501.V2" OR "20H/501Y.V2" OR "501Y.V2" OR "501.V2" OR South African Variant OR "B.1.1.28.1" OR "B.1.1.28" OR "B.1.1.248" OR
    [Show full text]
  • Creating the Fastest Economic Recovery
    x Chapter 1 Creating the Fastest Economic Recovery The beginning of 2020 ushered in a strong U.S. economy that was delivering job, income, and wealth gains to Americans of all backgrounds. By February 2020, the unemployment rate had fallen to 3.5 percent—the lowest in 50 years— and unemployment rates for minority groups and historically disadvantaged Americans were at or near their lowest points in recorded history. Wages were rising faster for workers than for managers, income and wealth inequality were on the decline, and median incomes for minority households were experienc- ing especially rapid gains. The fruits of this strong labor market expansion from 2017 to 2019 also included lifting 6.6 million people out of poverty, which is the largest three-year drop to start any presidency since the War on Poverty began in 1964. These accomplishments highlight the success of the Trump Administration’s pro-growth, pro-worker policies. The robust state of the U.S. economy in the three years through 2019 led almost all forecasters to expect continued healthy growth through 2020 and beyond. However, in late 2019 and the early months of 2020, the novel coronavirus that causes COVID-19, with origins in the People’s Republic of China, began spreading around the globe and eventually within the United States, causing a pandemic and bringing with it an unprecedented economic and public health crisis. Both the demand and supply sides of the economy suffered sudden and massive shocks due to the pandemic. During the springtime lockdowns aimed at “flattening the curve,” the labor market lost 22.2 million jobs, and the unemployment rate jumped 11.2 percentage points, to 14.7 percent—the largest monthly changes in the series’ histories.
    [Show full text]
  • COVID-19 & the Swedish Conundrum: Part I Why Did Sweden Not Lock
    COVID-19 & The Swedish Conundrum: Part I Why did Sweden not lock down? What were they trying to achieve? Prathap Tharyan The world is cautiously trying to emerge from lockdowns People enjoying the sun in Stockholm on April 21, 2020 Jonathan Nackstrand /AFP via Getty images (Business Insider May 4 2020) No Lockdown: Do the Swedes know something the rest of the world does not know? Or are they playing “Russian Roulette” with their “Herd Immunity” strategy? SWEDEN’S RELAXED CORONAVIRUS RESPONSE NO LOCKDOWN IN SWEDEN: A SOCIAL EXPERIMENT IN COMBATING COVID-19 Cafes, bars, restaurants, elementary schools and most businesses, including hair salons and gyms are open and people are allowed to exercise outdoors Parks and public spaces are open Pubs and bars remain open https://edition.cnn.com/2020/04/28/europe/sweden- Photograph: Ali Lorestani/EPA (The Guardian March 23) coronavirus-lockdown-strategy-intl/index.html WHY IS SWEDEN IS ‘DOING NOTHING’? Advice from the Public Health Agency Sweden has recommended good hygiene as part of infection control “Face masks are meant for Sweden’s Public Health Agency healthcare staff and not needed in in does not recommend face masks the community. for the public The best way to protect oneself and others in daily life is to maintain social distancing and good hand hygiene” SWEDISH PUBLIC HEALTH AGENCY RECOMMENDS SOCIAL DISTANCING No large gatherings (50 people max.) Does not apply to schools, public transport, gyms Work from home if possible Keep arms-length distance from others in all public spaces including
    [Show full text]
  • Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
    Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta.
    [Show full text]
  • Accelerating Vaccination Against Covid-19
    Accelerating vaccination against Covid-19 Press release of the French National Academy of Medicine April 12, 2021 The major challenge in overcoming the current health crisis is to acquire a sufficient herd immunity to control the circulation of SARS-CoV-2 and to consider the relaxation of restriction measures. Two factors contribute to this collective immunity: the proportion of people who have been infected since the beginning of the pandemic, estimated at 20% of the French population, and the vaccination coverage, which has just exceeded 18% of adults for the first injection. Post-infectious immunity is based on neutralizing antibodies that persist for more than one year after a moderate or severe form of Covid-19, and 6 to 8 months after an asymptomatic form [1], but also on the cellular response of T lymphocytes. This observation has led the French High Authority for Health to recommend that vaccination of immunocompetent individuals with confirmed SARS-CoV-2 infection be delayed for 3 to 6 months after the infectious episode and reduced to a single dose [2]. The vaccination coverage rate to reach the control of the epidemic has been increased to take into account the increased transmissibility of the B.1.1.7 variant, known as "British", which has become predominant throughout metropolitan France. According to the Pasteur Institute's modelling, more than 90% of the adult population would need to be vaccinated to achieve this objective, as long as the vaccination of children is not foreseen [3]. These estimates reinforce the prospect of a sustained circulation of SARS-CoV-2, which may lead to the emergence of new variants, with deleterious consequences on public health and the country's economy.
    [Show full text]
  • MRC Centre for Outbreak Analysis and Modelling
    Centre for Outbreak Analysis and Modelling MRC Centre for ANNUAL REPORT Outbreak Analysis and Modelling www.imperial.ac.uk/medicine/outbreaks 2012 The Centre specialises in quantitative epidemiology encompassing mathematical modelling, statistical analysis and evolutionary epidemiology, to aid the control and Director’s message treatment of infectious diseases. April 2013 sees the Centre renewed for a second 5-year Consortium (led by Tim Hallett) and the Vaccine Modelling term, after we received an unprecedented 10 out of 10 Initiative – are up for renewal. However, grants are only score from the MRC subcommittee, which assessed the one aspect of the relationship. As important are the close performance of the Centre over its first term. Just as the working relationships between staff in the Centre and the work of the Centre over that time has been very much a Foundation, which sees our research increasingly used to team effort, so was the success of the renewal. inform Foundation strategy and delivery. The last few months have seen us start to drive through Despite its title, the Centre’s mission rapidly evolved to our strategy for the next 5 years. A crucial aspect of this encompass delivering innovative epidemiological analysis is to boost capacity in key research areas. It is therefore not only of novel infectious disease outbreaks, but also of my pleasure to welcome new academic staff into the endemic diseases of major global health significance. Our Centre. Xavier Didelot joined us last year as a lecturer in work on polio, malaria and HIV reflects this. However, the pathogen genetics, and our expertise in evolutionary and last few months have highlighted the ongoing relevance of genetic research will be further boosted this year by the our original mission to enhance preparedness and response recruitment of at least one additional member of academic to emerging disease threats.
    [Show full text]
  • The Economics of a Pandemic: the Case of Covid-19
    The economics of a pandemic: the case of Covid-19 Paolo Surico and Andrea Galeotti Professors of Economics at London Business School london.edu Financial support from the European Research Council and the Wheeler Institute is gratefully acknowledged. This Lecture 1. Science 2. Health policies 3. Economics 4. Macroeconomic policies london.edu The economics of a pandemic: The case of Covid-19 2 The enemy Source: The Economist, 14th March 2020 london.edu The economics of a pandemic: The case of Covid-19 3 The basics about Covid-19: what it is • The cause: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) • The disease: Coronavirus disease 2019 (COVID-19) • Possible origin in wet animal market in Wuhan, China, early Dec 2019 • A strain of the same virus as SARS-CoV-1, which affected 8,000 people in 2002/03 • 96% DNA match between bat coronavirus and human found in a study from February; suggests link to humans is not direct but through intermediate host • Initially pangolins were suspected, but now seems to not be so; still unclear • Made of 4 proteins and a strand of RNA (molecule which can store genetic information) • One protein is the spike, which gives the crown-like appearance • Two proteins sit in the membrane between the spikes to provide structural integrity • In the membrane, the fourth protein is a scaffold around the genetic material Source: The Economist, 23rd January 2020; Nature: “Mystery deepens over animal source of coronavirus” https://www.nature.com/articles/d41586-020-00548-w london.edu The economics of a pandemic: The case of Covid-19 4 The basics about Covid-19: how it works • Enters through nose, mouth, or eyes.
    [Show full text]
  • News in Focus FEI/NYT/REDUX/EYEVINE SLAM YIK ​ Paramedics Transport a Man Thought to Be the First Person in Hong Kong to Have Contracted the New Coronavirus
    The world this week News in focus FEI/NYT/REDUX/EYEVINE SLAM YIK Paramedics transport a man thought to be the first person in Hong Kong to have contracted the new coronavirus. WHAT SCIENTISTS WANT TO KNOW ABOUT THE CORONAVIRUS OUTBREAK Researchers have sequenced the deadly pathogen’s genome — and are now rushing to find out how it spreads and how deadly it is. By Ewen Callaway and David Cyranoski Researchers fear similarities to the 2002–03 international concern — the agency’s highest epidemic of severe acute respiratory syn- level of alarm — after a meeting of officials last he world is racing to learn more about drome (SARS), which emerged in southern week, but that could change. the outbreak of a new viral infection that China and killed 774 people in 37 countries. Nature rounds up the questions at the heart was first detected in Wuhan, China, last Both are members of a large virus family, called of scientists’ efforts to understand the virus. month and is causing increasing alarm coronaviruses, that also includes viruses around the world. responsible for the common cold. How does the virus spread? TAs Nature went to press, officials in China China has taken unprecedented action to try This is the most urgent question surrounding had confirmed more than 4,500 cases of the to halt the outbreak — including putting Wuhan the outbreak. Chinese authorities have con- virus, which causes a respiratory illness, and and nearby cities on ‘lockdown’, restricting firmed that it spreads from person to person some 100 deaths. Around 50 cases had also travel in and out of the cities.
    [Show full text]
  • Special Edition - 5Th UPDATE 05/03/21
    IMMUNOWATCH Special edition - 5Th UPDATE 05/03/21 COVID-19 INTRODUCTION MabDesign and the COVID-19 pandemic The COVID-19 pandemic was matched by an unprecedented mobilisation of the French immunotherapy network and the pharmaceutical industry at large. Indeed, at the time of publication, three French companies already have preventive and/or therapeutic candidates currently undergoing Phase III clinical trials. In parallel, several bioprocessing sites across France have secured contracts for the production of both drugs and vaccines against SARS-CoV-2. These tremendous results were made possible through accelerated R&D as well as production and distribution logistics combined with facilitated access to information, resources and potential collaborators. MabDesign has been continuously adapting its actions and services to further support and enhance this nationwide pandemic response. Our latest and ongoing contribution to the fight against COVID-19 is through this special edition of Immunowatch and its regular updates. MabDesign’s Immunowatch is a one-of-a-kind information monitoring newsletter in the field of biomedicaments which aims at providing members of our association with the most recent and relevant data gathered or generated through the key expertise of MabDesign and its collaborators in scientific research, business intelligence, market analysis and intellectual property. Its original format has been modified to cater for the fast evolution of the response to the COVID-19 pandemic and allow rapid and pertinent updates. Immunowatch is done in collaboration with the MAbMapping Unit of the Ambition Recherche & Développement (ARD) Biomédicaments 2020 Phase II programme, funded by the Centre Val de Loire region. 2 Table of content 4.
    [Show full text]